EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors

Lingli Cai iD, Anqi Chen, Dong Tang

Immunology · 2024-10 · 173 (2) · 209-226

DOI: 10.1111/imm.13785 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 22.03.2024. Verfasst von Lingli Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College, Yangzhou University, Yangzhou, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Microsatellite Instability, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Hospital Level Management Project of Subei People's Hospital, the Social Development-Health Care Project of Yangzhou, Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a frequent gastrointestinal malignancy with high rates of morbidity and mortality; 85% of these tumours are proficient mismatch repair (pMMR)‐microsatellite instability‐low (MSI‐L)/microsatellite stable (MSS) CRC known as ‘cold’ tumours that are resistant to immunosuppressive drugs. Monotherapy with programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors is ineffective for treating MSS CRC, making immunotherapy for MSS CRC a bottleneck. Recent studies have found that the multi‐pathway regimens combined with PD‐1/PD‐L1 inhibitors can enhance the efficacy of anti‐PD‐1/PD‐L1 in MSS CRC by increasing the number of CD8+ T cells, upregulating PD‐L1 expression and improving the tumour microenvironment. This paper reviews the research progress of PD‐1/PD‐L1 inhibitors in combination with cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) inhibitors, oncolytic virus, intestinal flora, antiangiogenic agents, chemotherapy, radiotherapy and epigenetic drugs for the treatment of pMMR‐MSI‐L/MSS CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsMicrosatellite InstabilityProgrammed Cell Death 1 ReceptorImmunotherapyB7-H1 AntigenHumansTumor MicroenvironmentAnimalsCombined Modality Therapy

Stichwörter der Autor:innen

colorectal cancercombined modality therapyimmune checkpoint inhibitorsimmunotherapymicrosatellite stabilization

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenPDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Clinical Medical College, Yangzhou University, Yangzhou, China.
  • Department of General Surgery, Institute of General Surgery, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China.

ORCID-Profile: Lingli Cai

Förderung

  • Hospital Level Management Project of Subei People's Hospital
  • the Social Development-Health Care Project of Yangzhou, Jiangsu Province

Zitieren

APA

Cai, L., Chen, A., & Tang, D. (2024). A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors. Immunology, 173(2), 209-226. https://doi.org/10.1111/imm.13785

Vancouver

Cai L, Chen A, Tang D. A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors. Immunology. 2024;173(2):209-226. doi:10.1111/imm.13785

BibTeX
@article{Cai2024,
  author = {Cai, Lingli and Chen, Anqi and Tang, Dong},
  title = {A new strategy for immunotherapy of microsatellite‐stable (MSS) ‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD ‐1/ PD‐L1 inhibitors},
  journal = {Immunology},
  year = {2024},
  volume = {173},
  number = {2},
  pages = {209--226},
  doi = {10.1111/imm.13785}
}
Kostenlos starten →